# Pediatrix Medical Group, Inc.: financial statements, quarterly

MD · NYSE · CIK 893949 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/md.md) · [Financials](/companies/md/financials.md) · [Filings](/companies/md/filings.md) · [Insiders](/companies/md/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/md/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [496 d](/filings/0001193125-26-058074.md) | [495](/filings/0000950170-25-063951.md) | [504](/filings/0000950170-25-102382.md) | [511](/filings/0001193125-25-261640.md) | [502 d](/filings/0001193125-26-058074.md) | [458](/filings/0001193125-26-204993.md) | [469](/filings/0001193125-26-331513.md) | [493](/filings/0001193125-26-436952.md) | [494 d](/filings/0001193125-26-058074.md) | [476](/filings/0001193125-26-204993.md) | [488](/filings/0001193125-26-331513.md) | [501](/filings/0001193125-26-436952.md) |
| Operating income | $m | [(111) d](/filings/0001193125-26-058074.md) | [15.9](/filings/0000950170-25-063951.md) | [(158)](/filings/0000950170-25-102382.md) | [33.8](/filings/0001193125-25-261640.md) | [39.3 d](/filings/0001193125-26-058074.md) | [32.1](/filings/0001193125-26-204993.md) | [59.9](/filings/0001193125-26-331513.md) | [68.1](/filings/0001193125-26-436952.md) | [48.8 d](/filings/0001193125-26-058074.md) | [41.7](/filings/0001193125-26-204993.md) | [56.9](/filings/0001193125-26-331513.md) | [65.2](/filings/0001193125-26-436952.md) |
| Interest expense | $m | [10.1 d](/filings/0000950170-24-016794.md) | [10.6](/filings/0000950170-24-053922.md) | [10.3](/filings/0000950170-24-091193.md) | [10.1](/filings/0001193125-25-261640.md) | [9.7 d](/filings/0001193125-26-058074.md) | [9.2](/filings/0001193125-26-204993.md) | [9.1](/filings/0001193125-26-331513.md) | [8.9](/filings/0001193125-26-436952.md) | [8.7 d](/filings/0001193125-26-058074.md) | [8.3](/filings/0001193125-26-204993.md) | [8.2](/filings/0001193125-26-331513.md) | [8.1](/filings/0001193125-26-436952.md) |
| Income tax | $m | [(14.6) d](/filings/0001193125-26-058074.md) | [3.8](/filings/0000950170-25-063951.md) | [(14.7)](/filings/0000950170-25-102382.md) | [5.8](/filings/0001193125-25-261640.md) | [2.8 d](/filings/0001193125-26-058074.md) | [7.4](/filings/0001193125-26-204993.md) | [15.7](/filings/0001193125-26-331513.md) | [16.1](/filings/0001193125-26-436952.md) | [11.9 d](/filings/0001193125-26-058074.md) | [9.3](/filings/0001193125-26-204993.md) | [14.2](/filings/0001193125-26-331513.md) | [18.0](/filings/0001193125-26-436952.md) |
| Net income | $m | [(124) d](/filings/0001193125-26-058074.md) | [4.0](/filings/0001193125-25-261640.md) | [(153)](/filings/0001193125-25-261640.md) | [19.4](/filings/0001193125-25-261640.md) | [30.5 d](/filings/0001193125-26-058074.md) | [20.7](/filings/0001193125-26-436952.md) | [39.3](/filings/0001193125-26-436952.md) | [71.7](/filings/0001193125-26-436952.md) | [33.7 d](/filings/0001193125-26-058074.md) | [29.6](/filings/0001193125-26-436952.md) | [39.8](/filings/0001193125-26-436952.md) | [47.0](/filings/0001193125-26-436952.md) |
| Diluted EPS | $ per share | not reported | [0.05](/filings/0000950170-25-063951.md) | [(1.84)](/filings/0000950170-25-102382.md) | [0.23](/filings/0001193125-25-261640.md) | not reported | [0.24](/filings/0001193125-26-204993.md) | [0.46](/filings/0001193125-26-331513.md) | [0.84](/filings/0001193125-26-436952.md) | not reported | [0.36](/filings/0001193125-26-204993.md) | [0.49](/filings/0001193125-26-331513.md) | [0.59](/filings/0001193125-26-436952.md) |
| Basic EPS | $ per share | not reported | [0.05](/filings/0000950170-25-063951.md) | [(1.84)](/filings/0000950170-25-102382.md) | [0.23](/filings/0001193125-25-261640.md) | not reported | [0.25](/filings/0001193125-26-204993.md) | [0.46](/filings/0001193125-26-331513.md) | [0.85](/filings/0001193125-26-436952.md) | not reported | [0.37](/filings/0001193125-26-204993.md) | [0.50](/filings/0001193125-26-331513.md) | [0.61](/filings/0001193125-26-436952.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [73.3](/filings/0000950170-25-023730.md) | [8.0](/filings/0000950170-24-053922.md) | [19.4](/filings/0000950170-24-091193.md) | [104](/filings/0000950170-24-119796.md) | [230](/filings/0001193125-26-058074.md) | [99.0](/filings/0000950170-25-063951.md) | [225](/filings/0000950170-25-102382.md) | [340](/filings/0001193125-25-261640.md) | [375](/filings/0001193125-26-436952.md) | [206](/filings/0001193125-26-204993.md) | [289](/filings/0001193125-26-331513.md) | [312](/filings/0001193125-26-436952.md) |
| Current assets | $m | [483](/filings/0000950170-25-023730.md) | [427](/filings/0000950170-24-053922.md) | [429](/filings/0000950170-24-091193.md) | [528](/filings/0000950170-24-119796.md) | [640](/filings/0001193125-26-058074.md) | [492](/filings/0000950170-25-063951.md) | [613](/filings/0000950170-25-102382.md) | [717](/filings/0001193125-25-261640.md) | [764](/filings/0001193125-26-436952.md) | [587](/filings/0001193125-26-204993.md) | [660](/filings/0001193125-26-331513.md) | [684](/filings/0001193125-26-436952.md) |
| Total assets | $m | [2,220](/filings/0000950170-25-023730.md) | [2,168](/filings/0000950170-24-053922.md) | [1,995](/filings/0000950170-24-091193.md) | [2,077](/filings/0000950170-24-119796.md) | [2,153](/filings/0001193125-26-058074.md) | [1,993](/filings/0000950170-25-063951.md) | [2,102](/filings/0000950170-25-102382.md) | [2,199](/filings/0001193125-25-261640.md) | [2,247](/filings/0001193125-26-436952.md) | [2,070](/filings/0001193125-26-204993.md) | [2,130](/filings/0001193125-26-331513.md) | [2,139](/filings/0001193125-26-436952.md) |
| Current liabilities | $m | [389](/filings/0000950170-25-023730.md) | [247](/filings/0000950170-24-053922.md) | [310](/filings/0000950170-24-091193.md) | [373](/filings/0000950170-24-119796.md) | [434](/filings/0001193125-26-058074.md) | [271](/filings/0000950170-25-063951.md) | [341](/filings/0000950170-25-102382.md) | [393](/filings/0001193125-25-261640.md) | [459](/filings/0001193125-26-436952.md) | [443](/filings/0001193125-26-204993.md) | [502](/filings/0001193125-26-331513.md) | [536](/filings/0001193125-26-436952.md) |
| Total liabilities | $m | [1,371](/filings/0000950170-25-023730.md) | [1,312](/filings/0000950170-24-053922.md) | [1,289](/filings/0000950170-24-091193.md) | [1,344](/filings/0000950170-24-119796.md) | [1,388](/filings/0001193125-26-058074.md) | [1,204](/filings/0000950170-25-063951.md) | [1,268](/filings/0000950170-25-102382.md) | [1,309](/filings/0001193125-25-261640.md) | [1,381](/filings/0001193125-26-436952.md) | [1,192](/filings/0001193125-26-204993.md) | [1,249](/filings/0001193125-26-331513.md) | [1,290](/filings/0001193125-26-436952.md) |
| Long-term debt | $m | [622](/filings/0000950170-25-023730.md) | not reported | not reported | not reported | [611](/filings/0000950170-25-023730.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [849](/filings/0000950170-25-023730.md) | [856](/filings/0000950170-24-053922.md) | [706](/filings/0000950170-24-091193.md) | [732](/filings/0000950170-24-119796.md) | [765](/filings/0001193125-26-058074.md) | [789](/filings/0000950170-25-063951.md) | [834](/filings/0000950170-25-102382.md) | [891](/filings/0001193125-25-261640.md) | [866](/filings/0001193125-26-436952.md) | [879](/filings/0001193125-26-204993.md) | [881](/filings/0001193125-26-331513.md) | [850](/filings/0001193125-26-436952.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [69.3 d](/filings/0001193125-26-058074.md) | [(125)](/filings/0000950170-25-063951.md) | [107 d](/filings/0000950170-25-102382.md) | [91.8 d](/filings/0001193125-25-261640.md) | [133 d](/filings/0001193125-26-058074.md) | [(117)](/filings/0001193125-26-204993.md) | [137 d](/filings/0001193125-26-331513.md) | [137 d](/filings/0001193125-26-436952.md) | [114 d](/filings/0001193125-26-058074.md) | [(130)](/filings/0001193125-26-204993.md) | [125 d](/filings/0001193125-26-331513.md) | [117 d](/filings/0001193125-26-436952.md) |
| Share repurchases | $m | [0.0 d](/filings/0001193125-26-058074.md) | [0.9](/filings/0000950170-25-063951.md) | [0.0 d](/filings/0000950170-25-102382.md) | [0.2 d](/filings/0001193125-25-261640.md) | [0.6 d](/filings/0001193125-26-058074.md) | [1.6](/filings/0001193125-26-204993.md) | [0.2 d](/filings/0001193125-26-331513.md) | [20.9 d](/filings/0001193125-26-436952.md) | [64.0 d](/filings/0001193125-26-058074.md) | [21.5](/filings/0001193125-26-204993.md) | [42.7 d](/filings/0001193125-26-331513.md) | [83.0 d](/filings/0001193125-26-436952.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [82.3](/filings/0000950170-24-053922.md) | [82.7](/filings/0000950170-24-091193.md) | [83.0](/filings/0000950170-24-119796.md) | [83.3](/filings/0000950170-25-063951.md) | [83.3](/filings/0000950170-25-102382.md) | [84.5](/filings/0001193125-25-261640.md) | [85.4](/filings/0001193125-26-204993.md) | [85.5](/filings/0001193125-26-331513.md) | [85.6](/filings/0001193125-26-436952.md) | [83.1](/filings/0001193125-26-204993.md) | [81.4](/filings/0001193125-26-331513.md) | [79.7](/filings/0001193125-26-436952.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 78,124,716 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0001193125-26-436952.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 07:14 ET. No prices; not investment advice.